2C-T-7 (2,5-dimethoxy-4-(n)-propylthiophenethylamine) is one of the most notorious compounds to emerge from Alexander Shulgin's thio-phenethylamine series -- a psychedelic that earned both Shulgin's admiration and a body count. Catalogued as entry #40 in PiHKAL (1991), where Shulgin rated it a full +++, 2C-T-7 produces richly visual, emotionally deep psychedelic experiences lasting 8-12 hours at oral doses of 10-30 mg. The n-propylthio group at the 4-position of the phenethylamine ring gives the compound a warmth and organic character that users have compared more to tryptamines than to its 2C siblings -- earning it street names like "Blue Mystic" and "T-7" in the research chemical markets of the late 1990s and early 2000s.
What makes 2C-T-7 pharmacologically distinct from safer 2C compounds like 2C-B is the sulfur atom in its 4-substituent. That sulfur creates substrate interactions with monoamine oxidase enzymes, introducing a metabolic wildcard that can lead to unpredictable accumulation, amplified serotonergic effects, and -- at high doses or in combination with other serotonin-active substances -- full-blown serotonin syndrome. This is not theoretical. Between 2000 and 2001, multiple deaths in the United States were attributed to 2C-T-7, most involving doses well above Shulgin's recommended range, insufflation (which dramatically increases peak plasma levels), or combination with MDMA or DXM. Those deaths made 2C-T-7 a flashpoint in the emerging research chemical debate and directly catalyzed scheduling actions across multiple jurisdictions.
The tragedy of 2C-T-7 is that its subjective effects, by most accounts, are genuinely beautiful. The visuals carry an organic, almost biological quality -- mycelial networks, cellular geometries, vine-like traceries that feel alive and purposeful. The headspace is deep and introspective without the analytical harshness of 2C-E, and there is a warm empathogenic undercurrent that makes it feel more like a tryptamine cousin than a phenethylamine. But none of that changes the pharmacological reality: the thio-substitution that gives 2C-T-7 its character also gives it a risk profile that sits well outside the safety margins of classical psychedelics. The harm reduction community's position is unambiguous -- given the existence of 2C-B, psilocybin, and LSD, the risk-reward calculus does not favor this compound.
Safety at a Glance
High Risk- The Fundamental Risk Assessment
- Combinations That Have Killed People
- Toxicity: Documented Fatalities 2C-T-7 has directly caused deaths. Multiple fatalities were documented in the United States bet...
- Overdose risk: Recognizing a 2C-T-7 Emergency 2C-T-7 is one of the few psychedelics with a documented record of ...
If someone is in crisis, call 911 or Poison Control: 1-800-222-1222
Dosage
insufflated
oral
Duration
insufflated
Total: 3 hrs – 7 hrsoral
Total: 6 hrs – 10 hrsHow It Feels
The body arrives first. Within forty-five minutes of swallowing the dose, a warmth gathers in the stomach and spreads through the chest -- not unpleasant exactly, but accompanied by a gastrointestinal unease that is the price of entry for most thio-substituted 2C compounds. The nausea ranges from a mild background awareness to something genuinely distracting, and for some people the first hour involves a negotiation between the building psychedelic effects and the body's insistence that something foreign is being metabolized. Ginger helps. Lying still helps. Muscle tension settles into the shoulders and jaw, and there is a subtle stimulant undercurrent -- a low electrical hum running through the limbs. Colors begin shifting even as the stomach protests.
Around the ninety-minute mark, the nausea retreats and the experience opens like a door into a cathedral. The visual field transforms into something extraordinary. Colors become so saturated they seem to emit their own light -- not the crisp, digital precision of NBOMe visuals, but something organic and alive. Surfaces develop flowing geometric patterns that look biological: mycelial networks spreading across walls, cellular structures blooming and dividing, vine-like traceries weaving through the grain of wood. Closed-eye visuals are vast, slowly evolving landscapes of impossible depth. People who have experience with both phenethylamines and tryptamines consistently place 2C-T-7's visual character closer to psilocybin mushrooms than to 2C-B -- there is an earthy, natural quality to what you see, as though the patterns are growing rather than being generated.
The headspace is where 2C-T-7 earns its reputation. There is a pulling inward, a gravitational force toward introspection that rewards stillness and surrender. Emotional material surfaces with a gentle but persistent pressure -- not the aggressive analytical forcing of 2C-E, but a warm insistence on looking at things honestly. Relationships, patterns of behavior, beliefs you carry without examining -- they come up for review in a light that feels illuminating rather than harsh. Music becomes devastating in the best possible way, capable of triggering waves of catharsis that leave you wrung out and grateful. The body, once past the nausea, settles into a warm heaviness. Movement feels unnecessary. You want to sit in one place and let the experience work.
The peak sustains for four to six hours -- a long time to be that deep. Total effects stretch eight to twelve hours, and the descent is slow, marked by physical fatigue and a lingering emotional vulnerability. You feel opened up, as though something has been rearranged internally and has not quite settled back into place. Sleep does not come easily. The next day carries an afterglow of emotional clarity and a heightened sensitivity to beauty in ordinary things -- the kind of perceptual refresh that makes people understand why Shulgin gave it three plus signs.
Subjective Effects
The effects listed below are based on the Subjective Effect Index (SEI), an open research literature based on anecdotal reports and personal analyses. They should be viewed with a healthy degree of skepticism. These effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects.
Physical Effects
Physical(28)
- Abnormal heartbeat— Abnormal heartbeat (arrhythmia) is any deviation from the heart's normal rhythm — including beats th...
- Bodily control enhancement— Bodily control enhancement is the subjective feeling of improved physical precision, coordination, a...
- Changes in felt bodily form— Changes in felt bodily form is the experience of one's body feeling as though it has altered its phy...
- Dehydration— A state of insufficient bodily hydration manifesting as persistent thirst, dry mouth, and physical d...
- Diarrhea— Diarrhea is the occurrence of frequent, loose, or watery bowel movements as a side effect of certain...
- Difficulty urinating— Difficulty urinating, also known as urinary retention, is the experience of being unable to easily p...
- Dizziness— A sensation of spinning, swaying, or lightheadedness that impairs balance and spatial orientation, o...
- Excessive yawning— Involuntary, repeated yawning that occurs far more frequently than normal and often without the usua...
- Frequent urination— Increased urinary frequency beyond normal patterns, caused by diuretic effects or bladder irritation...
- Headache— A painful sensation of pressure, throbbing, or aching in the head that can range from a dull backgro...
- Increased blood pressure— Increased blood pressure (hypertension) is an elevation of arterial pressure above the normal 120/80...
- Increased bodily temperature— Increased bodily temperature (hyperthermia) is an elevation of core body temperature above the norma...
- Increased heart rate— A noticeable acceleration of heartbeat that can range from a subtle awareness of one's pulse to a fo...
- Muscle cramp— Muscle cramps are sudden, involuntary, and often painful contractions of muscles that occur as a sid...
- Muscle tension— Persistent partial contractions or tightening of muscles that produces uncomfortable stiffness, cram...
- Nausea— An uncomfortable sensation of queasiness and stomach discomfort that may or may not lead to vomiting...
- Physical euphoria— An intensely pleasurable bodily sensation that can manifest as waves of warmth, tingling electricity...
- Physical fatigue— Physical fatigue is a state of bodily exhaustion characterized by reduced energy, diminished capacit...
- Pupil dilation— A visible enlargement of the pupil diameter (mydriasis) that can range from subtle widening to drama...
- Sedation— A state of deep physical and mental calming that manifests as a progressive desire to remain still, ...
- Seizure— Uncontrolled brain electrical activity causing convulsions and loss of consciousness -- a life-threa...
- Serotonin syndrome— Serotonin syndrome is a potentially fatal medical emergency caused by excessive serotonergic activit...
- Stimulation— A state of heightened physical and mental energy characterized by increased wakefulness, elevated mo...
- Stomach bloating— Stomach bloating is the uncomfortable distension of the abdomen resulting from gas accumulation, flu...
- Stomach cramp— Stomach cramps are sharp, intermittent pains in the abdominal region that can occur when psychoactiv...
- Teeth grinding— An involuntary clenching and rhythmic grinding of the jaw muscles, known clinically as bruxism, that...
- Temperature regulation disruption— Impaired thermoregulation causing unpredictable fluctuations between feeling hot and cold, with risk...
- Watery eyes— Excessive tear production causing overflow tearing and blurred vision, commonly occurring during opi...
Tactile(1)
- Tactile enhancement— The sense of touch becomes dramatically heightened, making physical contact feel intensely pleasurab...
Cognitive & Perceptual Effects
Visual(14)
- After images— A visual phenomenon in which a faint, ghostly imprint of a previously viewed image persists in the v...
- Colour enhancement— An intensification of the brightness, vividness, and saturation of colors in the external environmen...
- Colour shifting— The visual experience of colors on objects and surfaces cycling through continuous, fluid transforma...
- Drifting— The visual experience of perceiving stationary objects, textures, and surfaces as appearing to flow,...
- Geometry— The experience of perceiving complex, ever-shifting geometric patterns superimposed over the visual ...
- Internal hallucination— Vivid, detailed visual experiences perceived within an imagined mental landscape that can only be se...
- Pattern recognition enhancement— An increased ability and tendency to perceive meaningful patterns, faces, and images within ambiguou...
- Perspective hallucination— A hallucinatory phenomenon in which the observer's visual perspective shifts from the normal first-p...
- Scenery slicing— The visual field fractures into distinct, cleanly cut sections that slowly drift apart from their or...
- Settings, sceneries, and landscapes— The perceived environment in which hallucinatory experiences take place, ranging from recognizable l...
- Symmetrical texture repetition— Textures appear to mirror and tessellate across surfaces in intricate, self-similar symmetrical patt...
- Tracers— Moving objects leave visible trails of varying length and opacity behind them, similar to long-expos...
- Transformations— Objects and scenery undergo perceived visual metamorphosis, smoothly shapeshifting into other recogn...
- Visual acuity enhancement— Vision becomes sharper and more defined than normal, as though a slightly blurry lens has been broug...
Cognitive(13)
- Analysis enhancement— A perceived improvement in one's ability to logically deconstruct concepts, recognize patterns, and ...
- Conceptual thinking— A shift in the nature of thought from verbal, linear sentence structures to intuitive, non-linguisti...
- Confusion— An impairment of abstract thinking marked by a persistent inability to grasp or comprehend concepts ...
- Delusion— A delusion is a fixed, false belief that is held with unshakeable certainty and is impervious to con...
- Immersion enhancement— A heightened capacity to become fully absorbed and engrossed in external media such as music, films,...
- Introspection— An enhanced state of self-reflective awareness in which one feels drawn to examine their own thought...
- Memory suppression— A dose-dependent inhibition of one's ability to access and utilize short-term and long-term memory, ...
- Novelty enhancement— A feeling of increased fascination, awe, and childlike wonder attributed to everyday concepts, objec...
- Personal bias suppression— A decrease in the personal, cultural, and cognitive biases through which one normally filters their ...
- Thought acceleration— The experience of thoughts occurring at a dramatically increased rate, as if the mind has been shift...
- Thought loops— Becoming trapped in a repeating cycle of thoughts, actions, and emotions that loops every few second...
- Time distortion— Subjective perception of time becomes dramatically altered — minutes may feel like hours, or hours p...
- Wakefulness— An increased ability to stay awake and alert without the desire to sleep. Distinct from stimulation ...
Multi-sensory(1)
- Scenarios and plots— Scenarios and plots are the narrative structures that emerge within hallucinatory states — coherent ...
Transpersonal(2)
- Ego death— A profound dissolution of the sense of self in which personal identity, memories, and the boundary b...
- Unity and interconnectedness— A profound sense that identity extends beyond the self to encompass other people, nature, or all of ...
Pharmacology
Mechanism of Action
2C-T-7 produces its psychedelic effects through partial agonism at serotonin 5-HT2A receptors, the same primary target shared by all classical psychedelics from LSD to mescaline. The compound also shows meaningful affinity at 5-HT2C receptors, contributing to mood modulation and the anxiogenic edge that can emerge at higher doses. The n-propylthio substituent at C4 provides moderate receptor affinity -- consistent with the compound's active dose range of 10-30 mg, placing it between the more potent 2C-T-2 (ethylthio, active at 12-25 mg) and the weaker members of the series.
The Thio Problem: MAO Interaction
The defining pharmacological concern for 2C-T-7 -- and the reason it has killed people while 2C-B has not -- is the sulfur-containing 4-substituent. Unlike the halogen in 2C-B or the alkyl group in 2C-D, the propylthio group creates substrate interactions with monoamine oxidase (MAO) enzymes. This has three dangerous consequences:
- Autoinhibition of metabolism -- 2C-T-7 may partially block the very enzyme responsible for breaking it down, causing the drug to accumulate in a dose-dependent, nonlinear fashion. A dose that is merely strong for one person can become toxic in another whose MAO enzyme expression runs lower
- Serotonergic amplification -- When combined with any other substance that increases serotonin (MAOIs, SSRIs, SNRIs, MDMA, DXM, triptans), the partial MAO inhibition from 2C-T-7 can create a cascade that overwhelms serotonin reuptake capacity and produces massive, uncontrolled serotonin accumulation
- Individual variability -- MAO enzyme levels vary substantially between individuals due to genetics, age, diet, and concurrent medications, making dose-response prediction inherently unreliable for thio-substituted compounds
Serotonin Syndrome Pathway
At high doses or in serotonergic combinations, 2C-T-7's dual action -- direct 5-HT2A agonism plus partial MAO inhibition -- can overwhelm the brain's serotonin clearance mechanisms. The result is serotonin syndrome: a constellation of neuromuscular hyperactivity (tremor, clonus, rigidity), autonomic instability (hyperthermia, tachycardia, blood pressure swings), and altered mental status (agitation, confusion, delirium). Severe cases progress to hyperthermia exceeding 41°C, rhabdomyolysis, disseminated intravascular coagulation, and death. This mechanism has no ceiling effect -- unlike the controlled serotonin elevation from a therapeutic SSRI, this pathway can escalate until organ systems fail.
Pharmacokinetics
Oral onset is 45-90 minutes, with peak effects at 2-4 hours and total duration of 8-12 hours. Intranasal administration dramatically compresses the onset to 5-15 minutes with much higher peak plasma concentrations, which is directly implicated in several fatal cases. The extended duration reflects slow hepatic metabolism, likely via CYP2D6-mediated pathways, with the thio group's MAO interaction further complicating clearance kinetics.
Detection Methods
Urine Detection
2C-T-7 is not specifically targeted by standard immunoassay-based urine drug panels. However, because 2C-x phenethylamines share structural features with amphetamines, they may trigger false positives on amphetamine immunoassays in some cases. The likelihood of cross-reactivity depends on the specific immunoassay manufacturer and the antibody selectivity used. Urine detection windows for 2C-T-7 are estimated at 24 to 72 hours following ingestion when analyzed by LC-MS/MS methods, though limited pharmacokinetic data exists for many 2C-x compounds.
Blood and Serum Detection
Blood detection windows for 2C-T-7 are approximately 6 to 24 hours after oral administration. Peak plasma concentrations typically occur 1 to 3 hours post-ingestion. The relatively short half-lives of most 2C-x phenethylamines mean that blood testing must be performed promptly to capture detectable concentrations. LC-MS/MS is the only reliable method for quantitative blood analysis.
Standard Drug Panel Inclusion
2C-T-7 is NOT specifically included on standard 5-panel, 10-panel, or 12-panel drug screens. The primary concern for individuals undergoing routine screening is the potential for amphetamine cross-reactivity on immunoassay-based panels. If a presumptive positive for amphetamines occurs, confirmatory testing by GC-MS or LC-MS/MS would not confirm amphetamine and the result would be reported as negative unless the laboratory specifically tests for 2C-x compounds. Most routine laboratories do not include 2C-x phenethylamines in their confirmatory panels.
Confirmatory Methods
Definitive identification of 2C-T-7 requires LC-MS/MS or GC-MS with appropriate reference standards. Some forensic toxicology laboratories include 2C-x phenethylamines in their extended novel psychoactive substance panels. Immunoassay cross-reactivity alone is insufficient for confirmation and would be resolved by standard confirmatory procedures. Quantitative analysis typically requires specific method development as these compounds are not part of routine clinical chemistry workflows.
Reagent Testing (Harm Reduction)
For harm reduction identification, the Marquis reagent is a primary screening tool for 2C-T-7. The Marquis reagent produces a brown to olive reaction with 2C-T-7. Given documented fatalities associated with this compound, identification is critically important. The Mecke reagent may provide additional color reactions that help differentiate between specific 2C-x variants. The Ehrlich reagent shows no reaction with 2C-x phenethylamines, which can help distinguish them from tryptamines and lysergamides. The Mandelin reagent may produce green to brown reactions depending on the specific compound. Using multiple reagents in combination provides the most reliable field identification, though reagent testing cannot determine purity or dosage.
Interactions
| Substance | Status | Note |
|---|---|---|
| 2-Aminoindane | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 2-FA | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 2-FEA | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 2-FMA | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 2,5-DMA | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 1,3-Butanediol | Low Risk & Synergy | Cross-tolerance exists; effects compound |
| 1B-LSD | Low Risk & Synergy | Cross-tolerance exists; effects compound |
| 1cP-AL-LAD | Low Risk & Synergy | Cross-tolerance exists; effects compound |
| 1cP-LSD | Low Risk & Synergy | Cross-tolerance exists; effects compound |
| 1cP-MiPLA | Low Risk & Synergy | Cross-tolerance exists; effects compound |
History
2C-T-7 was synthesized by Alexander Shulgin as part of his systematic exploration of thio-substituted phenethylamines -- a series of compounds in which sulfur-containing groups were placed at the 4-position of the 2,5-dimethoxy ring system to probe how that substitution affected psychedelic character. The compound appears as entry #40 in PiHKAL (1991), where Shulgin documented a dose range of 10-30 mg, a duration of 8-15 hours, and a rating of +++ -- his second-highest mark, indicating a full, meaningful psychedelic experience. He described the visuals as "richly colored" and the emotional quality as open and introspective.
Through the 1990s, 2C-T-7 circulated in small quantities within the psychedelic research community, acquired the street name "Blue Mystic," and developed a modest reputation as one of the more rewarding compounds in Shulgin's phenethylamine catalog. The early research chemical vendors of the late 1990s -- operating in a legal gray area where compounds not explicitly scheduled could be sold as "not for human consumption" -- began offering 2C-T-7 to a wider audience. For a brief window, it was one of the most sought-after novel psychedelics available.
That window closed violently. In 2000 and 2001, a series of deaths in the United States were linked to 2C-T-7. In April 2000, Jake Duroy, a 20-year-old in Oklahoma, died after insufflating what was reported to be 35 mg -- well above the active oral dose range and administered via a route that dramatically increases peak plasma levels. Additional fatalities followed, most involving doses far above Shulgin's range, intranasal administration, or combination with other serotonergic substances including MDMA and DXM. The cases generated extensive media coverage and congressional attention.
The DEA placed 2C-T-7 under emergency Schedule I scheduling in September 2002 as part of a broader action against research chemicals. The deaths were directly cited in scheduling proceedings and became central exhibits in the argument that unscheduled structural analogs could carry serious toxicity risk. Internationally, 2C-T-7 was subsequently controlled across the EU, UK, Canada, Australia, and most other jurisdictions with analog legislation.
The legacy of 2C-T-7 extends beyond its own scheduling. The 2000-2001 fatalities were among the first high-profile deaths attributed to "research chemicals" as a category, and they fundamentally shaped how regulators, harm reduction organizations, and the psychedelic community approached novel psychoactive substances. They demonstrated that safety data from a small number of careful researchers (Shulgin's bioassay group) could not be extrapolated to the broader population, and that structural analogs of well-characterized compounds could carry dramatically different risk profiles.
Harm Reduction
The Fundamental Risk Assessment
2C-T-7 carries a documented history of fatalities. Safer psychedelic alternatives -- 2C-B, psilocybin, LSD, mescaline -- produce comparable experiences without the MAO-mediated toxicity risk. The pharmacological reality is that thio-substituted 2C compounds occupy a fundamentally different safety category from their halogenated or alkyl-substituted cousins. If you have access to any of those alternatives, use them instead.
Combinations That Have Killed People
The following are not theoretical warnings -- they are derived from autopsy reports and toxicological analyses of actual deaths:
- DXM (dextromethorphan): Documented in multiple fatal cases. DXM inhibits serotonin reuptake; combined with 2C-T-7's serotonergic activity and MAO interaction, this creates a lethal serotonin toxicity pathway. Absolutely contraindicated
- MDMA: Documented in fatal cases. Massive serotonin release plus impaired serotonin clearance. Absolutely contraindicated
- MAOIs of any kind: Including ayahuasca, Syrian rue, harmaline, prescription MAOIs (phenelzine, tranylcypromine, moclobemide). Absolutely contraindicated
- SSRIs and SNRIs: Serotonin reuptake inhibition plus 2C-T-7's MAO interaction creates additive serotonin toxicity risk. Contraindicated
- Tramadol: Lowers seizure threshold and inhibits serotonin reuptake. Contraindicated
- Lithium: Anecdotal evidence of dramatically increased psychosis and seizure risk with psychedelics. Contraindicated
Route of Administration Matters
Intranasal insufflation of 2C-T-7 is implicated in several fatalities. Snorting compresses the onset to minutes, dramatically increases peak plasma levels, and causes excruciating nasal pain. The oral route provides a slower, more controllable absorption curve. Never insufflate this compound.
If Someone Chooses to Use Despite These Warnings
- Start at the absolute floor: 5-8 mg oral, no higher. Shulgin's 10-30 mg range was established with a tiny sample size
- Have a sober, informed sitter present for the entire 12+ hour duration
- Be within immediate reach of emergency medical services
- Use an accurate milligram scale (not volumetric estimation)
- Never combine with any other substance -- including alcohol and cannabis
- Never redose. The slow onset can tempt impatient people into dangerous dose stacking
Recognizing Serotonin Syndrome
This is a medical emergency. Signs appear on a spectrum:
- Mild: Agitation, restlessness, dilated pupils, sweating, diarrhea, rapid heart rate
- Moderate: Muscle twitching (clonus), hyperreflexia, tremor, fever above 38°C
- Severe: Sustained muscle rigidity, temperature above 41°C, seizures, delirium, cardiovascular instability
At any sign beyond mild, call emergency services immediately. Do not wait to see if it gets worse. Cooling measures (cold water, ice packs to armpits and groin) while waiting for help. Cyproheptadine is the specific serotonin antagonist used in hospital settings.
Toxicity & Safety
Documented Fatalities
2C-T-7 has directly caused deaths. Multiple fatalities were documented in the United States between 2000 and 2001, with additional suspected cases internationally. This is not a theoretical risk category -- it is an established record of lethal outcomes. The fatalities share common patterns:
- Doses substantially above Shulgin's documented active range (10-30 mg oral), often 35 mg or higher
- Intranasal administration, which compresses onset and amplifies peak plasma concentration
- Combination with MDMA, DXM, or other serotonergic substances
- Clinical features consistent with serotonin syndrome: severe hyperthermia, seizures, cardiovascular collapse, multi-organ failure
Serotonin Toxicity
The primary lethal mechanism in 2C-T-7 fatalities is serotonin syndrome progressing to cardiovascular collapse. The compound's dual action -- direct 5-HT2A agonism combined with MAO substrate interaction -- can produce runaway serotonin accumulation when the system is stressed by high doses or serotonergic co-administration. Severe serotonin syndrome presents with hyperthermia exceeding 41°C (106°F), sustained muscular rigidity, disseminated intravascular coagulation (DIC), rhabdomyolysis, and renal failure. Death typically results from cardiovascular collapse or multi-organ failure.
The DXM Interaction
The combination of 2C-T-7 with dextromethorphan (DXM) appears in multiple fatal case reports and warrants specific emphasis. DXM is a serotonin reuptake inhibitor widely available in over-the-counter cough medications. Combined with 2C-T-7's serotonergic agonism and MAO interaction, DXM creates a triple-threat serotonin toxicity pathway with no pharmacological ceiling. This combination has killed people and must be considered absolutely lethal.
Cardiovascular Effects
Even at non-lethal doses, 2C-T-7 produces significant cardiovascular stimulation: elevated heart rate, hypertension, and peripheral vasoconstriction. For individuals with undiagnosed cardiac conditions, arrhythmias, or congenital heart defects, these effects represent additional risk independent of serotonin toxicity.
Individual Variability
Perhaps the most dangerous feature of 2C-T-7's toxicity profile is its unpredictability between individuals. The same dose that produces a pleasant experience in one person can produce a life-threatening reaction in another. This variability is attributed to individual differences in MAO enzyme expression, which is genetically determined and varies substantially across populations. There is no way to predict, from prior experience or from body weight, where an individual falls on this spectrum.
Route-Dependent Toxicity
Intranasal administration is implicated in a disproportionate number of adverse events and fatalities relative to oral use. Insufflation bypasses first-pass hepatic metabolism, produces much higher peak plasma concentrations, and compresses the time to peak effect from 90 minutes to under 15 minutes. The dose-response curve for insufflated 2C-T-7 is steeper, less predictable, and shifted toward toxicity.
Absolute Contraindications
- MAOIs of any kind (prescription, herbal, dietary)
- DXM (dextromethorphan)
- MDMA or any serotonin-releasing agent
- SSRIs, SNRIs, triptans
- Lithium
- Stimulants (amphetamines, cocaine, cathinones)
- Tramadol
- Pre-existing cardiovascular disease
Addiction Potential
2C-T-7 has negligible addiction potential. Like virtually all serotonergic psychedelics, it does not produce the dopamine-mediated reinforcement that drives compulsive redosing with stimulants or opioids. The experience is intense, physically taxing, and long enough (8-12 hours) that most users report no desire to repeat it for weeks or months. Tolerance to 2C-T-7's psychedelic effects builds rapidly after a single dose, with substantially reduced effects if a second dose is taken within 48 hours. Full tolerance reset requires approximately 7-14 days. Cross-tolerance exists with all serotonergic psychedelics -- LSD, psilocybin, mescaline, and other 2C compounds will produce diminished effects for roughly a week after a 2C-T-7 experience. The compound is not associated with physical dependence, withdrawal symptoms, or craving. The primary concern is not addiction but acute toxicity -- 2C-T-7 is dangerous because it can kill you, not because it can hook you.
Overdose Information
Recognizing a 2C-T-7 Emergency
2C-T-7 is one of the few psychedelics with a documented record of fatal outcomes. Any adverse reaction should be taken seriously and escalated quickly. Do not assume that because "psychedelics are safe," a person in distress will be fine.
Early warning signs (act immediately):
- Sustained heart rate above 150 bpm
- Body temperature rising above 39°C (102°F)
- Muscle rigidity or involuntary jerking movements (clonus)
- Agitation progressing to confusion or delirium
- Profuse sweating with hot, flushed skin
- Seizures of any duration
Signs consistent with serotonin syndrome (call emergency services NOW):
- Temperature above 41°C (106°F) -- this is life-threatening
- Sustained muscle rigidity, especially in the legs
- Rapid, chaotic eye movements
- Loss of coordination, inability to speak coherently
- Loss of consciousness
Emergency Response
- Call emergency services immediately. Tell them: "Possible serotonin syndrome from a serotonergic drug. Body temperature is [X]. Heart rate is [X]." Do not withhold information about what was taken -- emergency physicians need to know
- Begin cooling. Remove excess clothing. Apply cold water or ice packs to armpits, groin, and neck -- the areas with major blood vessels closest to the surface. Fan the person. Evaporative cooling (misting with water while fanning) is the most effective field method
- Do not administer chlorpromazine or other antipsychotics. Unlike LSD emergencies, antipsychotics can worsen outcomes with serotonergic crises. Benzodiazepines (diazepam, lorazepam) are appropriate for agitation and seizures if available
- Monitor breathing. If the person becomes unconscious, place them in the recovery position. Be prepared to perform CPR if breathing or pulse stops
- Document timing. Note when the substance was taken, what dose, what route, and what other substances were involved. This information is critical for hospital treatment
Psychological Emergencies Without Physical Crisis
If the person is physically stable but experiencing severe anxiety, panic, or psychotic symptoms:
- Move to a quiet, low-stimulation environment
- Speak calmly and slowly. Use their name. Maintain eye contact
- Reassure them that the effects are temporary and time-limited
- Do not restrain unless there is immediate danger to self or others
- Benzodiazepines can reduce acute psychological distress if available
- If psychotic symptoms persist (hallucinations with loss of reality testing, paranoid delusions, self-harm behavior), seek emergency medical attention
Good Samaritan laws protect callers in most jurisdictions. Never let legal fear prevent you from calling for help.
Tolerance
| Full | almost immediately after ingestion |
| Half | 3 days |
| Zero | 7 days |
Cross-tolerances
Legal Status
In November 2003, the European Council decided that 2C-T-7 shall be subjected by the Member States to control measures and criminal penalties within three months.
Australia: In Australia, 2C-T-2 and 2C-T-7 are covered by the country's analog drug laws.
Austria: 2C-T-7 is illegal to possess, produce and sell under the SMG. (Suchtmittelgesetz Österreich)
Brazil: Possession, production and sale is illegal as it is listed on Portaria SVS/MS nº 344.
Canada: 2C-T-7 is considered Schedule III as it is a derivative of 2,5-dimethoxyphenethylamine.
China: As of October 2015 2C-T-7 is a controlled substance in China.
Germany: 2C-T-7 is controlled under Anlage I BtMG (Narcotics Act, Schedule I) as of July 1, 2001. It is illegal to manufacture, possess, import, export, buy, sell, procure or dispense it without a license.
Latvia: 2C-T-7 is a Schedule I controlled substance in Latvia.
The Netherlands: The Netherlands was the first country in the world to ban 2C-T-7 after being sold in smart shops for a short period. After 2C-T-2 was first banned, 2C-T-7 quickly appeared on the market but was soon banned as well. 2C-T-7 is a list I drug of the Opium Law.
Sweden: The drug is Schedule I in Sweden. 2C-T-7 was first classified as a health hazard under the act "Lagen om förbud mot vissa hälsofarliga varor" (translated as "the Act on the Prohibition of Certain Goods Dangerous to Health") that made it illegal to sell or possess as of April 1, 1999.
Switzerland: 2C-T-7 is a controlled substance specifically named under Verzeichnis D.
United Kingdom: 2C-T-7 is a Class A drug in the United Kingdom as a result of the phenethylamine catch-all clause.
United States: On September 20, 2002, 2C-T-7 was classified as a Schedule I substance in the United States by an emergency ruling by the DEA. On March 18, 2004, the DEA published a final rule in the Federal Register which permanently placed 2C-T-7 in Schedule I.
Responsible use
Research chemical
Psychedelic
2C-T-2
Hardison, C. (2000). An amateur qualitative study of 48 2C-T-7 subjective bioassays. MAPS Bulletin, 10(11).
2C-T-7 (Wikipedia)
2C-T-7 (Erowid Vault)
2C-T-7 (PiHKAL / Isomer Design)
Discussion
The Big & Dandy 2C-T-7 Thread (Bluelight)
Experience Reports (1)
Tips (3)
Use a milligram scale to weigh 2C-T-7 if it comes as a powder. Eyeballing doses of potent psychedelics is irresponsible. A quality 0.001g scale costs under $30 and could prevent a seriously overwhelming experience.
Psychedelic tolerance builds rapidly. Wait at least 1-2 weeks between uses of 2C-T-7 for full tolerance reset. Taking the same dose the next day would require roughly double the amount for comparable effects.
Clear your schedule for the full duration of 2C-T-7 plus afterglow. Do not plan any obligations, driving, or important decisions for the day. Having a time pressure or commitment hanging over you adds unnecessary anxiety.
See Also
References (4)
- Psilocybin produces substantial and sustained decreases in depression and anxiety — Griffiths et al. Journal of Psychopharmacology (2016)paper
- Neural correlates of the LSD experience revealed by multimodal neuroimaging — Carhart-Harris et al. PNAS (2016)paper
- 2C-T-7 - TripSit Factsheet
TripSit factsheet for 2C-T-7
tripsit - 2C-T-7 - Wikipedia
Wikipedia article on 2C-T-7
wikipedia